GitFlash Research · October–November 2026
What Still Protects Big Pharma?
AI, trillion-dollar valuations and the future of drug patents.
AI could shorten a medicine’s economic life before its patent expires. The decisive question is who controls the route from discovery to patients.
Research publication · 20 pages · PDF · 5.7 MB · English · Published 2 October 2026 · Facts as at 27 September 2026
A patent protects a medicine for a fixed term. AI-accelerated discovery could let a better successor arrive before that term ends, shortening the period in which a medicine earns its return.
The issue reads market valuations, development-cost and clinical evidence, and the funders now shaping access — Coefficient Giving, NGOs, Gates, Anthropic and the next generation of philanthropic and technology funders.
Cheaper discovery can strengthen incumbents if they own the next treatments, while trials, manufacturing and delivery remain costly.
What this issue covers
- A market-capitalisation chart of the largest pharmaceutical companies
- Development-cost and clinical evidence
- An access map: where medicines reach patients, and where they do not
- Coefficient Giving, NGOs, Gates, Anthropic and the next generation of funders
- The counterargument: cheaper discovery that strengthens incumbents
Scope and limitations
The research evidence cutoff is 27 September 2026. The period label refers to the months the issue addresses, not to a publication date.
It offers a conditional reading. It does not predict an industry collapse and does not claim a measured advantage for any funder.
It draws on 36 selected linked sources across 20 pages: 16 interior pages and four cover pages.
GitFlash Research is an institutional publication of GitFlash. It is not commissioned by, and not affiliated with, any government body or court.